Vitamed, Rekah Group

Company Overview

Snapshot

Founded in January 1947, Vitamed, part of Rekah Group, operates with 11–50 employees. The company became public on TASE in January 1994, marking a significant milestone in its journey as a generic pharmaceutical manufacturer.

Business overview

Vitamed, a division of Rekah Pharmaceutical Industries, specializes in the manufacturing of generic pharmaceuticals. The company is actively expanding its global footprint through out-licensing, in-licensing, strategic partnerships, and mergers and acquisitions. Rekah Group manages the entire value chain, from R&D and production to marketing, sales, distribution, import, and export. Its diverse portfolio encompasses 280 generic prescription and over-the-counter drugs, dermo-cosmetics, vitamins, and nutritional supplements, with a core focus on steroids, antibiotics, ophthalmic medications, and over-the-counter drugs. The group serves global markets, operating in the Health Tech & Life Sciences sector.

Company Intelligence Q&A

When did Vitamed, Rekah Group become a public company?

Vitamed, Rekah Group became a public company with an Initial Public Offering on TASE in January 1994.

What is Vitamed's primary business focus?

Vitamed, as part of Rekah Group, primarily focuses on generic pharmaceutical manufacturing, aiming to increase its international presence through various strategic initiatives.

What types of products does Rekah Group offer?

Rekah Group offers a wide range of products including 280 generic prescription and over-the-counter drugs, dermo-cosmetics, vitamins, and nutritional supplements, with specialties in steroids, antibiotics, and ophthalmic medications.

Where are Rekah Group's research and development laboratories located?

Rekah Group operates research and development laboratories at its production sites in Holon and Binyamina.

What was a notable strategic development for Rekah in August 2018?

In August 2018, Rekah announced plans to take over some of Teva Israel's production operations.